SFPI-FPIM

Tangent Works is a data science startup specializing in real-time predictive analytics. The company has developed a platform that automates the repetitive and manual tasks traditionally associated with data science, particularly in model building. By leveraging advancements in machine learning, Tangent Works bridges the gap between academic research and practical industry applications. Its technology uncovers hidden dynamics within data, enabling businesses to generate accurate predictive models for time series analysis. This innovative approach allows machine learning services to be executed directly on devices, enhancing operational efficiency and decision-making for organizations.

Cohabs is a provider of rental co-living spaces that offers fully furnished shared homes for nomads worldwide. The company focuses on creating a network of sustainable and community-oriented residences that cater to the needs of its members. Cohabs enhances the living experience by providing amenities such as weekly cleaning, shared groceries, and monthly breakfasts. In addition, the company fosters a vibrant community through organized events, dinners, and social gatherings, promoting interaction among residents. By prioritizing flexibility and a tech-driven approach, Cohabs aims to create an enriching environment for individuals seeking adaptable living arrangements.

Axelera AI is a company focused on advancing artificial intelligence through its specialized hardware and software platforms, particularly for edge computing applications. Its flagship product, the Metis™ AI Platform, combines innovative hardware and software to offer high-performance and energy-efficient AI inference solutions. Recognized for its innovation, the platform was honored at the CES® 2024 Innovation Awards. Established in 2021, Axelera AI was incubated by Bitfury, a leader in emerging technologies, and partnered with imec, a prominent nano-technology group. The company is headquartered in the AI Innovation Center at the High Tech Campus in Eindhoven, with research and development offices located in Belgium, Switzerland, and Italy. The team consists of experts in AI software and hardware, many of whom have backgrounds with leading AI firms and Fortune 500 companies. Axelera AI’s platform features a unique custom dataflow architecture with multicore in-memory computing, enabling clients to achieve optimal power efficiency while supporting various networks for sustainable edge applications.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Magnax is a company that specializes in yokeless axial flux technology, which is used to create high power density motors for electric powertrains and aerospace propulsion systems. Their innovative motors are designed with a patented cooling system that maintains low stator temperatures, enhancing robustness and efficiency. This technology reduces core losses through the use of oriented electrical steel, allowing manufacturers in the e-mobility sector to develop lighter and more energy-efficient vehicles. Magnax operates through strategic subsidiaries, such as Traxial, which focuses on ground-based e-mobility applications, and Axyal, which targets the aerospace market, each requiring tailored approaches to effectively serve their respective industries.

EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses primarily on the treatment of glaucoma, a condition historically managed with daily eye drops. EyeD Pharma aims to enhance the quality of life for patients by reducing the side effects associated with traditional therapies. In collaboration with ophthalmologists, the company offers new treatment options and surgical products that improve clinical practices and provide therapeutic assistance that is currently lacking in the market. Through its efforts, EyeD Pharma seeks to advance the standard of care in ophthalmology.

PDC*line Pharma is a clinical-stage biotech company based in France and Belgium, specializing in the development of innovative active immunotherapies for cancer. The company utilizes a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells (PDC*line) that are loaded with cancer antigens to enhance the immune response against tumors. Founded in April 2014 in Grenoble by Laurent Levy and Joel Plumas, PDC*line Pharma evolved from a research program at the French Blood Bank that developed the PDC line from a patient with PDC leukemia. The company aims to provide more effective cancer treatments by leveraging these potent and scalable dendritic cell lines to boost antitumor responses, including those targeting neoantigens, and to stimulate specific cytotoxic T-cell activity beyond what conventional vaccines can achieve. Eric Halioua joined the company in 2016 and has since served as President and CEO, guiding its progression into clinical development.

Qpinch is a company focused on transforming wasted industrial heat into valuable process heat, thereby generating carbon-neutral steam and reducing energy costs for various industries. By utilizing an innovative chemical heat transformer, Qpinch helps businesses optimize their existing industrial assets, leading to immediate energy savings while minimizing their environmental impact. The company's technology allows clients to effectively repurpose waste heat, contributing to a more sustainable energy landscape and enhancing operational efficiency.

Itsme is a mobile application that provides secure digital authentication services, allowing users to verify their identity and safely engage in online transactions. The platform facilitates a range of functions, including logging in to various digital services, confirming online payments, accessing government applications, and signing official documents electronically. By assigning a unique identification to transactions, Itsme ensures user privacy while navigating online environments. The app is designed to deliver a reliable and user-friendly experience for individuals seeking to manage their digital identities securely.

Imcyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, specializing in innovative immunotherapeutic solutions aimed at treating severe chronic autoimmune diseases. Founded in 2010, Imcyse is pioneering a unique technology platform that employs Imotopes™, specifically modified peptides that target immune cells responsible for organ damage. This approach facilitates the generation of cytolytic CD4 T-cells, which selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, thereby addressing diseases with limited treatment options. The company has shown proof of concept across various indications and has completed its initial clinical trial for type 1 diabetes, yielding promising outcomes. In addition to type 1 diabetes, Imcyse is actively developing a pipeline of therapies for multiple autoimmune diseases, aiming to provide effective treatment while preserving overall immune defense.

Endo Tools Therapeutics S.A., established in 2008 and based in Gosselies, Belgium, is a medical device company focused on creating innovative devices for gastroenterologists. The company develops therapeutic devices that enhance interventional gastroenterology, including a triangulation platform known as ENDOMINA. This open platform enables gastroenterologists to perform a variety of therapeutic procedures more effectively. Endo Tools Therapeutics is also working on a catheter designed to provide additional therapeutic channels and enhanced maneuverability during interventions. The company's products aim to improve treatment options for conditions such as obesity, digestive tract tumors, and diabetes by facilitating flexible endoscopic suturing and tissue apposition, thereby enabling more efficient surgical endoscopy.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Miracor Medical is a medical device company that specializes in developing clinical devices aimed at treating severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company is known for its PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion technology. This innovative system is designed to assist cardiac surgeons in treating patients experiencing myocardial infarction during coronary artery bypass grafting procedures. By enhancing microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size, improve cardiac function, and potentially decrease the likelihood of heart failure following acute myocardial infarction.

ExeVir Bio BV is a Belgian biotechnology company founded in 2020 and headquartered in Zwijnaarde. The company specializes in developing single-domain antibody-based therapies aimed at preventing viral infections. Utilizing a llama-derived antibody technology platform, ExeVir Bio focuses on creating robust antiviral treatments, particularly targeting coronaviruses. One of its key products, VHH72-FC, binds to a conserved region of the SARS-CoV-2 spike protein, which is crucial for the virus's entry into human cells. The company has established a rapid response platform for antivirals, allowing for a quick adaptation to emerging health threats through a streamlined process for generating drug candidates. Their protein-based therapeutics are designed to be stable, cost-effective, and accessible on a global scale, addressing significant public health challenges posed by viral infections.

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics aimed at improving outcomes for cancer patients. Founded in 2011 and headquartered in Gosselies, Belgium, with additional operations in Cambridge, Massachusetts, the company is advancing a pipeline of innovative drug candidates. Notable among these is EOS-850, a small molecule antagonist targeting the adenosine A2a receptor, currently undergoing an open-label Phase 1/2a clinical trial in adult patients. Another key candidate is EOS-448, an antagonist of TIGIT, which is also in Phase 1/2a trials. iTeos leverages expertise in tumor immunology to create small molecule immunomodulators designed to counteract cancer-induced immune suppression, thereby enhancing the effectiveness of existing treatments and emerging immunotherapies.

OncoDNA is a theranostic and genomic company that specializes in precision medicine for cancer and genetic diseases. Founded by a team with over 60 years of experience in medical diagnostics, the company focuses on providing clinical guidance for the treatment and real-time monitoring of late-stage cancer patients. OncoDNA supports researchers and biopharma companies in navigating the complexities of molecular biology, facilitating research and drug development in oncology. With its commitment to delivering precision medicine, OncoDNA aims to enhance treatment outcomes and improve the management of cancer and genetic disorders.

iSTAR Medical SA is a Belgian company specializing in the development of innovative ophthalmic implants aimed at treating glaucoma. Founded in 2010 as a spinout of Healionics Corporation, the company has established itself in the field with its flagship product, the STARflo glaucoma implant. This non-degradable, precision-pore device functions as a micro-porous drainage system that reduces intraocular pressure by enhancing the eye’s natural uveoscleral outflow. iSTAR Medical's offerings also include STARflo PLUS and STARflo MINI surgical therapies, which incorporate anti-fibrotic and anti-inflammatory properties to improve patient outcomes. The company operates from its eco-friendly R&D and manufacturing facility in CREALYS Scientific Park near Namur, Belgium, and distributes its products through various international partners across Europe and Asia. iSTAR Medical is committed to providing advanced and effective treatment alternatives for glaucoma patients, with its devices designed to limit inflammation and fibrosis while promoting bio-integration with surrounding tissues.

Ninepointfive is a venture capital investment firm based in Antwerp, Belgium, founded in 2017. It specializes in co-investing with corporate partners to support technology-based startups from pre-seed funding through to maturity. The firm collaborates with established brands to help founders maximize the value of corporate acceleration. Ninepointfive employs a proprietary methodology that emphasizes speed, growth, and active engagement, ensuring a pragmatic approach to investment. The firm's focus spans various sectors, including energy, financial services, healthcare, information technology, and both B2B and B2C markets.

Unifly is a developer of unmanned traffic management software focused on the secure integration of drones into global airspace. Founded in 2015 by aerospace experts, the company emerged from a vision shared by air traffic controllers who recognized the need for effective management of the increasing number of drones. Unifly's award-winning platform connects authorities and drone operators, allowing for real-time monitoring and management of drone traffic, while providing pilots with essential information regarding the legal status of their flights. The platform is already utilized by national authorities in Germany, Denmark, Austria, and Belgium, and Unifly is also active in the United States and several projects worldwide, including Africa and Asia. By fostering collaboration with various stakeholders, Unifly aims to enhance airspace safety and facilitate the seamless integration of drones into everyday life, addressing critical concerns regarding safety and oversight in both recreational and commercial drone activities.

Imcyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, specializing in innovative immunotherapeutic solutions aimed at treating severe chronic autoimmune diseases. Founded in 2010, Imcyse is pioneering a unique technology platform that employs Imotopes™, specifically modified peptides that target immune cells responsible for organ damage. This approach facilitates the generation of cytolytic CD4 T-cells, which selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, thereby addressing diseases with limited treatment options. The company has shown proof of concept across various indications and has completed its initial clinical trial for type 1 diabetes, yielding promising outcomes. In addition to type 1 diabetes, Imcyse is actively developing a pipeline of therapies for multiple autoimmune diseases, aiming to provide effective treatment while preserving overall immune defense.

Endo Tools Therapeutics S.A., established in 2008 and based in Gosselies, Belgium, is a medical device company focused on creating innovative devices for gastroenterologists. The company develops therapeutic devices that enhance interventional gastroenterology, including a triangulation platform known as ENDOMINA. This open platform enables gastroenterologists to perform a variety of therapeutic procedures more effectively. Endo Tools Therapeutics is also working on a catheter designed to provide additional therapeutic channels and enhanced maneuverability during interventions. The company's products aim to improve treatment options for conditions such as obesity, digestive tract tumors, and diabetes by facilitating flexible endoscopic suturing and tissue apposition, thereby enabling more efficient surgical endoscopy.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Miracor Medical is a medical device company that specializes in developing clinical devices aimed at treating severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company is known for its PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion technology. This innovative system is designed to assist cardiac surgeons in treating patients experiencing myocardial infarction during coronary artery bypass grafting procedures. By enhancing microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size, improve cardiac function, and potentially decrease the likelihood of heart failure following acute myocardial infarction.

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics aimed at improving outcomes for cancer patients. Founded in 2011 and headquartered in Gosselies, Belgium, with additional operations in Cambridge, Massachusetts, the company is advancing a pipeline of innovative drug candidates. Notable among these is EOS-850, a small molecule antagonist targeting the adenosine A2a receptor, currently undergoing an open-label Phase 1/2a clinical trial in adult patients. Another key candidate is EOS-448, an antagonist of TIGIT, which is also in Phase 1/2a trials. iTeos leverages expertise in tumor immunology to create small molecule immunomodulators designed to counteract cancer-induced immune suppression, thereby enhancing the effectiveness of existing treatments and emerging immunotherapies.

Air Belgium S.A., established in 1979 and headquartered in Mont-Saint-Guibert, Belgium, specializes in passenger air transportation with a focus on intercontinental flights between Belgium and select destinations in Asia, including Hong Kong. The airline operates a diverse fleet equipped with economy, premium, and business class seating, catering to various passenger needs. In addition to providing comfortable in-flight experiences, Air Belgium also accommodates travelers with pets and children, and offers onboard catering services. The company is committed to delivering quality air travel at competitive prices, ensuring an enjoyable journey for its customers.

Synergia Medical is focused on the development and commercialization of next-generation neurostimulation devices, leveraging optoelectronics technology. The company specializes in creating MRI-safe, implantable neurostimulators designed primarily for drug-resistant epilepsy, with potential applications in various therapeutic areas. By replacing traditional wires with fiber optics, Synergia's devices utilize photovoltaic cells to convert optical energy into electrical impulses, enhancing their functionality and safety. Over a brief period of three years, Synergia Medical has achieved ISO13485 certification, successfully developed and marketed an OEM external neurostimulator for motorized prosthetic arms, and launched its initial NAOS platform. Supported by private investors and public research grants, the company has expanded its team to thirteen highly skilled professionals with extensive experience in the field, underscoring its commitment to innovation in neurostimulation technology.

PharmaFluidics is a Brussels-based spin-off from the Vrije Universiteit Brussel, focusing on developing and manufacturing micro-chip based chromatography columns for use in biomarker, diagnostics, and drug research applications. The company leverages its expertise in chemical engineering and micro-fabrication technology to create high-quality solutions tailored for mixing, separation, and reaction processes at milli- to nano-scales. Their products enable researchers to identify active compounds in complex biological samples more efficiently and sensitively.

Miracor Medical is a medical device company that specializes in developing clinical devices aimed at treating severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company is known for its PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion technology. This innovative system is designed to assist cardiac surgeons in treating patients experiencing myocardial infarction during coronary artery bypass grafting procedures. By enhancing microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size, improve cardiac function, and potentially decrease the likelihood of heart failure following acute myocardial infarction.

Ncardia is a biotechnology company focused on expediting the drug discovery and development process. Utilizing human induced pluripotent stem cell (hiPSC) technology, Ncardia develops predictive human cellular assay systems that facilitate safety and efficacy testing of drug candidates. The company's innovations enhance cardiovascular and neural drug screening, allowing researchers and drug discovery firms to incorporate predictive human disease biology into their processes. Through its advanced technologies, Ncardia aims to accelerate the overall drug discovery timeline, ultimately improving the efficiency and effectiveness of bringing new therapeutics to market.

Ncardia is a biotechnology company focused on expediting the drug discovery and development process. Utilizing human induced pluripotent stem cell (hiPSC) technology, Ncardia develops predictive human cellular assay systems that facilitate safety and efficacy testing of drug candidates. The company's innovations enhance cardiovascular and neural drug screening, allowing researchers and drug discovery firms to incorporate predictive human disease biology into their processes. Through its advanced technologies, Ncardia aims to accelerate the overall drug discovery timeline, ultimately improving the efficiency and effectiveness of bringing new therapeutics to market.

PDC*line Pharma is a clinical-stage biotech company based in France and Belgium, specializing in the development of innovative active immunotherapies for cancer. The company utilizes a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells (PDC*line) that are loaded with cancer antigens to enhance the immune response against tumors. Founded in April 2014 in Grenoble by Laurent Levy and Joel Plumas, PDC*line Pharma evolved from a research program at the French Blood Bank that developed the PDC line from a patient with PDC leukemia. The company aims to provide more effective cancer treatments by leveraging these potent and scalable dendritic cell lines to boost antitumor responses, including those targeting neoantigens, and to stimulate specific cytotoxic T-cell activity beyond what conventional vaccines can achieve. Eric Halioua joined the company in 2016 and has since served as President and CEO, guiding its progression into clinical development.

iSTAR Medical SA is a Belgian company specializing in the development of innovative ophthalmic implants aimed at treating glaucoma. Founded in 2010 as a spinout of Healionics Corporation, the company has established itself in the field with its flagship product, the STARflo glaucoma implant. This non-degradable, precision-pore device functions as a micro-porous drainage system that reduces intraocular pressure by enhancing the eye’s natural uveoscleral outflow. iSTAR Medical's offerings also include STARflo PLUS and STARflo MINI surgical therapies, which incorporate anti-fibrotic and anti-inflammatory properties to improve patient outcomes. The company operates from its eco-friendly R&D and manufacturing facility in CREALYS Scientific Park near Namur, Belgium, and distributes its products through various international partners across Europe and Asia. iSTAR Medical is committed to providing advanced and effective treatment alternatives for glaucoma patients, with its devices designed to limit inflammation and fibrosis while promoting bio-integration with surrounding tissues.

NovoPolymers NV is a company focused on creating sustainable solutions tailored for the photovoltaic market. It specializes in the development and production of front and back encapsulants that protect solar cells. These encapsulants are designed to enhance the power output of both crystalline silicon and thin-film solar modules, thereby adding value across the photovoltaic supply chain. Through its innovative products, NovoPolymers aims to contribute to the advancement of renewable energy technologies.

Promethera Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver diseases. Founded in 2009 and based in Mont-Saint-Guibert, Belgium, with an office in Tokyo, Japan, the company specializes in cell therapy products, notably HepaStem and H2Stem, which utilize allogeneic progenitor cells derived from healthy human adult livers. Promethera is actively working on treatments for a range of conditions, including acute-on-chronic liver failure, hemophilia, liver fibrosis, non-alcoholic steatohepatitis, liver-based metabolic diseases, and urea cycle disorders. The company also engages in strategic alliances to further its research and development efforts, enhancing its capacity to discover and commercialize effective cell therapies for liver-related ailments.

IBA engages in the distribution of crop protection and cattle feed products.

NovoPolymers NV is a company focused on creating sustainable solutions tailored for the photovoltaic market. It specializes in the development and production of front and back encapsulants that protect solar cells. These encapsulants are designed to enhance the power output of both crystalline silicon and thin-film solar modules, thereby adding value across the photovoltaic supply chain. Through its innovative products, NovoPolymers aims to contribute to the advancement of renewable energy technologies.

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics aimed at improving outcomes for cancer patients. Founded in 2011 and headquartered in Gosselies, Belgium, with additional operations in Cambridge, Massachusetts, the company is advancing a pipeline of innovative drug candidates. Notable among these is EOS-850, a small molecule antagonist targeting the adenosine A2a receptor, currently undergoing an open-label Phase 1/2a clinical trial in adult patients. Another key candidate is EOS-448, an antagonist of TIGIT, which is also in Phase 1/2a trials. iTeos leverages expertise in tumor immunology to create small molecule immunomodulators designed to counteract cancer-induced immune suppression, thereby enhancing the effectiveness of existing treatments and emerging immunotherapies.

NovoPolymers NV is a company focused on creating sustainable solutions tailored for the photovoltaic market. It specializes in the development and production of front and back encapsulants that protect solar cells. These encapsulants are designed to enhance the power output of both crystalline silicon and thin-film solar modules, thereby adding value across the photovoltaic supply chain. Through its innovative products, NovoPolymers aims to contribute to the advancement of renewable energy technologies.